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1. Introduction 
Intermediate filaments (IFs) are the most stable components in the cells, and are involved in 
many important physiological functions, including distribution of organelles, signal 
transduction, cell polarity and gene regulation. (Iwatsuki & Suda,  2010).  
Cytokeratins (CK or CKs) are the largest complex group of IF proteins. These are proteins, 
that are crucial in the development and differentiation of epithelial cells, as well as 
essential for normal tissue structure and function. The first keratin protein nomenclature 
was published by Moll et al. (1982) and it has been repeatedly updated in recent years 
(Schweizer et al., 2006). Based on the results of ongoing research in human and other 
vertebrates, Szeverenyi et al. (2008) published a comprehensive catalogue of the human 
keratins, their amino acid sequence, the nucleotide sequence of the keratin genes in 
humans, as well as the same data of the orthologue keratins and keratin genes in various 
vertebrate species. Based on their molecular weights and isoelectric points CKs were 
catalogued and divided into two groups: type I and type II cytokeratins. The type I 
cytokeratins  consist of acidic, low molecular weight (40-56.5 kDa) proteins including 
cytokeratins K9-K28 and hair keratins K31-K40. The type II cytokeratins consist of basic, 
high molecular weight (52-67 kDa) proteins including cytokeratins K1-K8, cytokeratins 
K71-K80 and hair keratins K81-K86 (Bragulla & Homberger, 2009; Iwatsuki & Suda, 2010; 
Moll et al., 2008; Schweizer et al., 2006). Cytokeratins are relatively resistant to 
degradation and show highly specific phenotypic expression depending on the type and 
differentiation of the epithelial cells. Hence, the different types of epithelia have specific 
for them pattern of keratin expression.  
Based on biochemical and immunohistochemical studies, it was possible to explain and 
define the epithelial tissue-specific distribution of CKs but also to conclude that tumors 
arising from a given epithelium generally preserved this pattern of CK expression despite 
malignant transformation. Moreover, the cytokeratin expression patterns in a given type of 
tumor appear to be identical in primary tumors and their metastases, independent from the 
specific location and size (Lam et al., 2001; Moll et al., 1982). Therefore, antibodies against 
various cytokeratins are important in the accurate identification and classification of 
different types of carcinomas, whose origin is uncertain by routine light microscopy. In this 
context, the diverse expression patterns of CK7 and CK 20 among epithelial tumors have 
been proposed to help discriminating primary from metastatic carcinoma of various origins 
(Duval et al., 2000; Nikitakis et al., 2004; Wauters et al., 1995). Based on the differential 
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staining patterns for cytokeratins reported in the literature, in the following chapter, we 
focused on evaluation of utility of cytokeratins 7 and 20 both in differential diagnosis of 
tumors and identification of the primary site of tumor origin. 
2. Characterization and distribution of cytokeratins 7 and 20 in tissues 
2.1 Cytokeratin 7 
Cytokeratin 7 (CK7) is a polypeptide with molecular weight 54 kDa and an isoelectric point 
at pH 6.0. (Bragulla & Homberger, 2009; Moll et al., 1982; Schweizer et al., 2006). This 
protein is encoded by the KRT7 gene, located on chromosome 12q13.13 (Bragulla & 
Homberger, 2009, Schweizer et al., 2006). In normal tissues, this basic (type II) keratin is 
found to be distributed in a wide variety of simple epithelia: in organs associated with the 
gastrointestinal tract (including only the gallbladder, hepatic ducts and pancreatic ducts), 
female genital tract (the ovary, endometrium, fallopian tube and cervix), breast, urinary tract 
(the cells of the renal tubule and collecting ducts of the kidney, as well as in the cells of the 
transitional epithelium of the mucosa of the renal  pelvis, ureter and bladder), and 
respiratory tract (the sinonasal mucosa, trachea and lung) (Iwatsuki & Suda, 2010; Moll et 
al., 1982, 2008).  Cytokeratin 7 is found in epithelial cells of fetal stomach, whereas in normal 
gastrointestinal epithelium is undetectable (Tatsumi et al., 2005). It is also one of the several 
cytokeratins, which are expressed in the developing teeth of human (in the developing 
stratified enamel organ) (Bragulla & Homberger, 2009). In endometrium, CK7 expression is 
high in secretory phase but low in the proliferative phase of the estrous cycle. Cytokeratin 7 
is also expressed in the epithelial cells of the nail bed epidermis and in mesothelium and 
endothelial cells. Moreover, CK7 has been shown to be expressed to a different degree in the 
various epithelial salivary gland elements; more specifically, immunohistochemicaly the 
luminal cells of the salivary ducts are strongly positive for CK7, while the acinar, basal, and 
myoepithelial cells stain with less intensity (Nikitakis et al., 2004). Cytokeratin 7 was 
undetectable in hepatocytes, proximal and distal tubules of the kidney, and squamous cell 
epithelia. 
2.2 Cytokeratin 20 
Cytokeratin 20 (CK20) is a newly described polypeptide with molecular weight 48.5 kDa 
and an isoelectric point at pH 5.66 (Bragulla & Homberger, 2009; Moll et al., 1993; 
Schweizer et al., 2006). This protein is encoded by the KRT20 gene, located on 
chromosome 17q21.2 (Bragulla & Homberger, 2009, Schweizer et al., 2006).  CK20 was 
originally identified as protein “IT” in cytoskeletal extracts of intestinal epithelia. In 
normal human tissues this acidic (type I) keratin is found in more complex epithelia of the 
gastrointestinal tract (such as taste buds, gastric foveolar cells and intestinal epithelium), 
urothelial umbrella cells, squamous epithelia from any site and Merkel cells of the 
epidermis and hair follicle outer root sheath (Barret et al., 2000; Jovanovic et al., 2002; Moll 
et al., 2008). In human embryogenesis, it appears in the small intestinal epithelium at 
embryonic week 8 (Moll et al., 2008). No cytokeratin 20 expression was identified in 
mesothelium (Tot, 2002), sinonasal epithelia (Franchi et al., 2004) and any salivary gland 
epithelial elements (Nikitakis et al., 2004). 
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3. Application of cytokeratins 7 and 20 in diagnostic pathology 
3.1 Expression of CK7 in primary tumors and their metastases 
The frequency of CK 7 expression is summarized in Figure 1. Generally positive 
immunohistochemical cytokeratin 7 expression has been identified in carcinomas of the 
breast, lung, endometrium and ovaries. Moreover, primary tumors of the sinonasal tract, 
thyroid gland, salivary gland, biliary and urinary tract stain strongly positive for CK7.  
Fig. 1. Percentage of positive expression of CK7 in primary and metastatic adenocarcinomas 
(based on Tot, 2002) 
Even some primary brain neoplasms, like choroid plexus tumors, as well as malignant 
mesotheliomas and synovial sarcomas are CK7+. Taking to account the different histological 
subtypes of cancer, CK7 positivity has been reported in 100% of cases of papillary thyroid 
carcinoma (86/86), follicular thyroid carcinoma (19/19) and medullary thyroid carcinoma 
(13/13) (Lam et al., 2001) as well as mucinous (6/6), nonmucinous (4/4) and mixed (6/6) 
bronchioloalveolar adenocarcinoma (Chu et al., 2000; Simsir et al., 2004).  
The same percentage of positive immunostaining for CK7 was detected in seven histologic 
types of salivary gland carcinoma, including mucoepidermoid, adenoid cystic, 
polymorphous low grade, salivary duct, acinic cell, clear cell and basal cell (Nikitakis et al., 
2004). Poorly differentiated and anaplastic thyroid carcinomas expressed CK7, but the 
number of immunoreactive cells was smaller than those in well-diferentiated carcinomas. 
Similarly the percentage of CK7 positive cases of urothelial carcinoma was lower in high-
grade tumors  infiltrating the surrounding tissues (67%), than in low-grade urothelial 
carcinoma (100%) (Bassily et al., 2000). This may be due to the loss of cytokeratin expression 
during tumor progression into high-grade lesion.  
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It is also worth noting that distribution of cytokeratin 7 staining varied among different 
histological types of some tumors, which may be useful in their discrimination. An example 
of this is the report by Nikitakis et al. (2004) on salivary gland tumors, describing focal 
staining of CK7 in adenoid cystic carcinoma compared to the universally diffuse pattern in 
polymorphous low-grade adenocarcinoma. Also, there was a report of strong cytoplasmic 
and membrane CK7 staining in chromophobe variant of renal cell carcinoma distinguishing 
it from benign oncocytomas showing focal weak-to-moderate CK7 cytoplasmic staining 
(Campbell & Herrington, 2001). Among soft tissue sarcomas CK7 expression has been found 
in a small proportion of liposarcomas (7%), gastrointestinal stromal tumors (12%) and 
epithelioid (25%) (Humble et al., 2003) and synovial sarcomas. Other sarcomas, including 
malignant fibrous histocytoma, leiomyosarcoma, angiosarcoma, malignant peripheral nerve 
sheath tumor, desmoids tumor, rhabdomyosarcoma and primitive neuroectodermal tumor 
were negative for CK7 (Campbell & Herrington, 2001). Prostate adenocarcinomas, 
hepatocellular carcinomas and most of gastric carcinomas also have been negative for 
keratin 7, despite of small proportion of these tumor cases showing CK7 positive expression 
(Bassily et al., 2000; Chu et al., 2000; Sawan, 2009). 
Nevertheless, the lack of immunoreactivity in colorectal adenocarcinomas is the main point 
of diagnostic utility of this keratin in differentiation adenocarcinoma metastases in context 
of their possible primary tumor. Eighty-eight percent of metastases from colorectal 
adenocarcinoma to the lung, liver, lymph nodes, chin, small bowel, peritoneum and bone 
were negative for CK7 ( Kummar et al., 2002). Respectively, 62.5 % (Rekhi et al., 2008) and 
76.4% (Wauters et al., 1995) of colorectal adenocarcinoma metastases to the ovary were also 
negative for CK7. Despite the lack of expression of cytokeratin 7, some cases of colorectal 
adenocarcinoma show positive immunoreactivity for CK7. This positive rate for CK7 is 0-
16% in primary tumors, and 8.3-19% in metastatic cancers. In contrast, almost 100% and 73% 
immunoreactivity for CK7 has been detected in primary and metastatic pulmonary 
adenocarcinomas respectively.  
3.2 Expression of CK20 in primary tumors and their metastases 
The frequency of CK 20 expression is summarized in Figure 2. CK20 expression is restricted to 
a few organ systems. Almost all cases of colon carcinoma (91-100%) were positive for CK20, as 
well as 64-78% of urothelial tumors, 78% of Merkel cell tumors, 50-71% of adenocarcinomas of 
the stomach, 55% of biliary adenocarcinomas and 44-62% of adenocarcinomas of the pancreas 
(Chu et al., 2000; Duval et al., 2000; Stopyra et al., 2001; Tot, 2002). 
Moreover, high percentage (84%) of sinonasal intestinal-type adenocarcinomas (ITACs) was 
CK20 positive, which distinguished them from non-ITACs showing lack of 
immunoreactivity for CK20 (Franchi et al., 2004). Similarly, in the case of renal oncocytomas 
a high degree of CK20 positive immunoreactivity (80%) can be a useful diagnostic tool to 
distinguish them from renal cell carcinomas, in which no or weak positive reaction (range 0-
7.7%) has been found (Stopyra et al., 2001). 
In all of the colorectal lesions high CK20 positivity was found, including 100% in 
hyperplastic polyps, 95% in serrated adenomas, 90% in conventional adenomas and 92% in 
adenocarcinomas. Generally, pulmonary adenocarcinomas are negative for CK20 (Campbell 
& Herrington, 2001; Hatanaka et al., 2011; Kummar et al., 2002). Nevertheless, positive 
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immunoreactivity for CK20 has been detected in 5 (83%) of 6 cases of mucinous and in all (6) 
cases of mixed bronchioloalveolar carcinoma (Simsir et al., 2004), as well as in 5 (32%) of 16 
cases of pulmonary adenocarcinoma with enteric differentiation (Hatanaka et al., 2011). All 
cases of nonmucinous bronchioloalveolar carcinomas were negative for CK20 (Simsir et al., 
2004). For this reason, distinguishing primary pulmonary adenocarcinomas from metastases 
with strong CK20 expression may be difficult. There are some differences in CK20 
expression in ovarian adenocarcinomas. About 67% of ovarian mucinous adenocarcinomas 
were positive for CK20, while among non-mucinous ovarian tumors 25% (62/246) 
expressed CK20 (Tot, 2002; Wauters et al., 1995). The lack of reaction, or sporadic focal and 
weak CK20 immunostaining is detected in salivary gland tumors, except small cell 
carcinomas, that frequently display diffuse positivity for CK20. Those cases included: 2 
(7.7%) of 26 cases of mucoepidermoid carcinoma, 1 (4%) of 25 cases of adenoid cystic 
carcinoma and 3 (37.5%) of 8 cases of salivary duct carcinoma (Nikitakis et al., 2004), as well 
as 6 (10%) of 59 cases of prostate adenocarcinoma (Campbell & Herrington, 2001) and 2 (6%) 
of 30 cases of squmous cell carcinoma of the head and neck (Chu et al., 2000). So far, no 
cytokeratin 20 expression has been found in soft tissue sarcomas, such as epithelioid 
sarcoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, 
leiomyosarcoma, angiosarcoma, desmoids tumor, rhabdomyosarcoma and primitive 
neuroectodermal tumor (Campbell & Herrington, 2002). Lack of CK20 reactivity was also 
reported in all thyroid carcinomas (Lam et al., 2001), thymomas, mesotheliomas (Campbell 
& Herrington, 2001), and squamous cell carcinomas of the cervix (Chu et al., 2000; Nikitakis 
et al., 2004).  
 
Fig. 2. Percentage of positive expression of CK20 in primary and metastatic 
adenocarcinomas (based on Tot 2002) 
Strong stability of the CK20 expression in colorectal adenocarcinomas (Table 2), that retain 
during their metastatic progression allows for specific recognition of metastases of this type 
of tumor. Ninety-two percent of metastases of the colorectal cancers to the lung, liver, 
lymph nodes and small bowel were positive for CK20 (Tot, 2002; Kummar et al., 2002). 
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Colorectal adenocarcinomas metastatic to the ovary also showed CK20 positivity in all cases. 
However, in the latter case, primary mucinous ovarian carcinomas can not be excluded, due 
to their positive expression of CK20. The fact, that tumors retain expression of CK20 during 
their metastases, is useful in detection of circulating cancer cell in the peripheral blood, 
using reverse transcriptase (RT)-PCR analysis. It is a very helpful method to detect 
metastases at a very early stage of disease, especially in case of colorectal carcinoma, gastric 
and pancreatic adenocarcinoma as well as lung carcinoma (Moll et al., 2008; Wang et al., 
2006). The same method is used in early detection of bladder cancer in voided urine (Pu et 
al., 2007). 
3.3 CK7/CK20 phenotype in primary tumors and metastases 
Among epithelial tumors approximately 80% are malignant (Chu et al., 2000).  
Metastatic tumors from an uknown primary site are a common clinical problem, that leads 
to extensive and costly clinical and radiological examinations, sometimes with 
disappointing results. A proper diagnosis of the primary site is important for therapeutic 
decision-making and prognosis of particular tumor types.  
Possibility of identifying the primary tumors in cases of unclear metastases is significantly 
increased when CK7 is used in combination with CK20, since many carcinomas exhibit 
characteristic CK7/CK20 phenotypes. For the determination of these phenotypes several 
monoclonal antibodies against CK7 and CK20 are used (Upasani et al., 2004). Most 
commonly used antibodies, their dilutions and the antigen retrieval methods are presented 
in Table 1. For comparison, the distribution of reported CK7/CK20 phenotype of different 
types of tumor in the reviewed literature is presented in Table 2. Differences between a 
specific type of tumor and its CK7/CK20 phenotype found in the collected literature make it 
difficult to compare the results. Therefore, the data presented in the table should be 
considered as a collection of information published so far. 
The majority of the tumor cases from the gastrointestinal and genitourinary tracts, which 
have been described so far show CK7+/CK20+ phenotype. This phenotype is also very 
specific for mucinous and mixed bronchioloalveolar adenocarcionomas (BACs) and differs 
from typical CK7+/CK20- phenotype of conventional pulmonary adenocarcinoma. This 
immunohistochemical staining is crucial for distinguishing mucinous and mixed BACs from 
metastatic adenocarcinomas involving the lungs. Nevertheless, distinction of mucinous 
BACs from metastatic mucinous adenocarcinomas of gastrointestinal, pancreatic, and 
ovarian origins can be difficult, due to the same CK7+/CK20+ phenotype. To distinguish 
prostate carcinoma from urothelial carcinoma CK7+/CK20+ phenotype is helpful for ruling 
out prostate cancer, as it is extremely rarely (0-2%) present in prostate carcinoma (Bassily et 
al. 2000). Immunophenotype CK7-/CK20+ is most useful in distinguish primary and 
metastatic tumors from the colorectal tumors and Merkel cell carcinomas (Saeb-Lima et al., 
2008). However, it should be kept in mind, that some of recently described primary 
pulmonary adenocarcinomas with enteric differentiation (12.5%) express the same 
phenotype (Hatanaka et al., 2011).  
Large number of different type of tumors express different percentage of CK7+/CK20- 
phenotype (Table 2), that is the most specific for tumors of the lungs, sinonasal tract, 
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salivary gland and thyroid gland (Franchi et al., 2004; Lam et al., 2001; Kummar et al., 2002; 
Nikitakis et al., 2004). Therefore, it is not possible to differentiate these tumor types, based 
solely on cytokeratin 7 expression. Knowledge of the CK7/CK20 immunophenotype of 
tumors in case of distant metastases may be valuable in their definitive diagnosis, especially 
in the lack of a previous diagnosis of a primary tumor. It can be important in case of 
metastases of colorectal carcinoma and breast tumors to the skin (Fidler et al., 2007). Tumors 
of the skin and soft tissue, which have been reported so far, express mainly CK7-/CK20- 
phenotype, beside Merkel cell carcinomas. 
 
Antibody Clone Dilution Source Antigen retrieval method 
 OV-TL 12/30 1:12.5 Dako without pretreatment 
 OV-TL 12/30 1:50 Dako 0.05% pronase , 37 ºC 
 OV-TL 12/30 1:60 Dako 0.1% pronase, RT (10 min) 
 OV-TL 12/30 1:100 Dako 
0.01 M citrate buffer pH 6, 
microwave (15 min) 
 OV-TL 12/30 1:100 Bio Genex 
0.1% pronase in Tris-HCl 
buffer, 37ºC (5 min) 
Cytokeratin 7 OV-TL 12/30 1:200 Dako 
0.01 M citrate buffer pH 6, 
microwave (5 min) 
 OV-TL 12/30 1:800 Bio Genex 
0.5% protease XIV 20ºC (15 
min) 
 OV-TL 12/30 1:1900 Dako 
proteinase K (ready-to-use), RT 
(10 min) 
 LDS-68 1:32000 Sigma 
0.4% pepsin in 0.01 N 
hydrochloric acid, 37ºC (15 min) 
Cytokeratin 20 Ks 20.8 1:10 Dako 
0.1% pronase in Tris-HCl 
buffer, 37ºC (5 min) 
 Ks 20.8 1:10 Dako without pretreatment 
 Ks 20.8 1:50 Dako 
boiled in 10 mm citrate buffer 
pH 6 
 Ks 20.8 1:60 Dako 0.1% pronase, RT (10 min) 
 Ks 20.8 1:60 Bio Genex 
0.5% protease XIV 20ºC (15 
min) 
 Ks 20.8 1:100 Dako 
0.01 M citrate buffer pH 6, 







0.01 M citrate buffer pH 6, 
microwave (20 min) 
Cytokeratin 20 
(NCL-CK20) 
Ks 20.8 1:1350 Novocastra
proteinase K (ready-to-use), RT 
(10 min) 
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mixed BAC 100 0 0 0 
mucinous BAC 83 17 0 0 
nonmucinous BAC 0 100 0 0 
PAED 18.75 68.75 12.5 0 
adenocarcinoma 8-10 84-96 0 0 
carcinoid tumors 0 22 0 78 
small cell carcinoma 0 43 0 57 
squamous cell 
carcinoma 
0 47 0 53 
neuroendocrine 
carcinoma 
0 56 0 44 
Sinonasal 
tract 
ITAC 80 8 4 8 
non-ITAC 0 100 0 0 
Salivary 
gland 
salivary duct carcinoma 37.5 62.5 0 0 
mucoepidermoid 
carcinoma 
7.7 92.3 0 0 
AdCC 4 96 0 0 
PLGA 0 100 0 0 
ACC 0 100 0 0 
Ca-ex-MT 0 100 0 0 
CCC 0 100 0 0 
BCAC 0 100 0 0 
Thyroid 
gland 
papillary carinoma 0 100 0 0 
follicular carcinoma 0 100 0 0 
insular carcinoma 0 60 40 0 
anaplastic carcinoma 0 84 0 16 
medullary carcinoma 0 100 0 0 
Thymus thymoma 0 0 0 100 




0 9-12.5 9 82-87.5 
neuroendocrine 
carcinoma 
0 56 0 44 
Biliary tract 
cholangiocarcinoma 24-43 50-76 0 7-13 
gallbladder carcinoma 27 55 0 18 




76 14 0 0 
nonmucinous 
adenocarcinoma 
7 93 0 0 
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Uterus endometrial carcinoma 0 100 0 0 
 
cervical squamous cell 
carcinoma 




0 95 0 5 
infiltrating lobular 
carcinoma 
0 100 0 0 
Kidney 
renal oncocytoma 60 20 20 0 




61 21 4 14 
transitional cell 
carcinoma 
25 63 4 8 
Prostate adenocarcinoma 0-2 0-9 0-14 81-100 
Colon 
serrated adenoma 71 4.5 25 0 
hyperplastic polyp 68 0 32 0 
adenocarcinoma 5-8.3 1-2.1 83-100 0-6.3 
conventional adenoma 5 0 85 10 
neuroendocrine 
carcinoma 
0 56 0 44 
Mesothelium malignant mesothelioma 0 65 0 35 
Skin and soft 
tissue 
merkel cell carcinoma 0 0 78 12 
epithelioid sarcoma 0 0 0 100 
MPNST 0 0 0 100 
MFH 0 0 0 100 
leiomyosarcoma 0 0 0 100 
angiosarcoma 0 0 0 100 
desmoids tumor 0 0 0 100 
rhabdomyosarcoma 0 0 0 100 
primitive 
neuroectodermal tumor
0 0 0 100 
Abbreviations: BAC, bronchioloalveolar adenocarcinoma; PAED, pulmonary adenocarcinoma with 
enteric differentiation; ITAC, intestinal-type adenocarcinoma; AdCC, adenoid cystic carcinoma; PLGA, 
polymorphous low-grade adenocarcinoma; ACC, acinic cell carcinoma; Ca-ex-MT, carcinoma ex mixed 
tumor; CCC, clear cell carcinoma; BCAC, basal cell adenocarcinoma; MPNST, malignant peripheral 
nerve sheath tumor; MFH, malignant fibrous histiocytoma. 
Table 2. Distribution of CK7/CK20 phenotype in different types of tumors of different 
organs (based on references: Bassily et al., 2000;  Cambell & Harrington, 2001; Chu et al., 
2000; Duval et al., 2000; Hatanaka et al., 2011;  Humble et al., 2003; Kummar et al., 2002;Lam 
et al., 2001; Nikitakis et al., 2004; Rekhi et al., 2008; Saeb-Lima et al., 2008; Sawan, 2009; 
Simsir et al., 2004; Stopyra et al., 2001; Tatsumi et al., 2005; Tot, 2002; Wauter at al., 1995)  
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This chapter shows that the CK7/CK20 phenotype of tumors can be a valuable diagnostic 
marker in the determination of the primary site of origin of metastatic tumor (Fig. 1, 2, Table 
2). Detection of CK7+/CK20- phenotype indicates metastatic carcinoma, most often from the 
lungs, salivary gland or breast in bone, ovaries, liver, colon and even in bone marrow. The 
CK7-/CK20+ phenotype indicates metastatic carcinoma, usually from the colorectal region 
mainly in lungs and ovaries. Whereas, the CK7-/CK20- phenotype indicates metastatic 
carcinoma often from the prostate, mainly in bone. However, the different CK7/CK20 
immunophenotypes do not show 100% specificity and sensitivity for any tumor. Therefore, 
CK7 and CK20 should be used as a part of an immunohistochemical panel of antibodies. 
Despite the fact, that the data presented in this chapter come from reports from recent years, 
further studies involving cases of tumors with clearly identified primary location, tumor 
type and subtype are necessary to confirm these results and to extend CK phenotyping to 
rare tumor types. Moreover, further studies are needed for evaluation of RT-PCR for CK20 
mRNA in serum, blood, urine for the identification of tumor cells. Due to the relatively 
widespread expression of cytokeratin 7 in epithelial cells of various organs, further research 
related to the gene KTR7 (Pujal et al., 2009) could be useful in therapeutic strategies for 
epithelial neoplasms.   
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